MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

Meeting: 2019 International Congress

Abstract Number: 125

Keywords: Alpha-synuclein, Orthostatic hypotension(OH), Pharmacotherapy

Session Information

Date: Monday, September 23, 2019

Session Title: Clinical Trials, Pharmacology and Treatment

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies.

Background: nOH is due to failure of the autonomic nervous system to adequately increase synaptic norepinephrine (NE) to maintain upright blood pressure (BP). A norepinephrine reuptake inhibitor (NRI) could augment local synaptic concentrations of tonically released NE, at the vascular sympathetic neuroeffector junction, resulting in increased BP and reduced symptoms of orthostatic hypotension. Ampreloxetine is a novel NRI being investigated for the treatment of subjects with symptomatic nOH.

Method: This was a 24-week open-label Phase 2 multicenter study of subjects with nOH. After a single-dose escalation phase, responders were treated with ampreloxetine (3 to 20 mg) taken orally once-daily for up to 20 weeks and followed for 4 weeks thereafter. Primary endpoint for efficacy was OHSA#1 at Week 4, durability was assessed at Week 20 and following withdrawal of treatment at Week 24.

Results: 21 subjects were enrolled in the open-label phase (mean age 64 years; 57% MSA). Of these, 16 (76%) completed the Week 4 assessment, 11 (52%) completed Week 20 and 10 (48%) were assessed at Week 24. The mean [SD] improvement from baseline in OHSA#1, OHSA and OHDAS composite scores are provided below. Table 1 Table 2 The most frequently reported AEs were urinary tract infection (24%), hypertension (19%), and headache (14%). Two subjects (10%) discontinued treatment due to AEs and 5 (24%) reported SAEs, none considered related to the study medication.

Conclusion: In subjects with nOH, ampreloxetine demonstrated clinically meaningful improvements in OHSA#1 at Week 4. The improvement in OHSA#1 was sustained through Week 20. Symptoms reverted back to baseline during the 4-week withdrawal. A similar trend was observed in OHSA and OHDAS composite scores.  Ampreloxetine was generally well-tolerated.

MDS Abstract Table 1

MDS Abstract Table 2

To cite this abstract in AMA style:

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery. A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/a-phase-2-study-of-the-efficacy-durability-and-safety-of-ampreloxetine-td-9855-a-norepinephrine-reuptake-inhibitor-given-once-daily-to-treat-neurogenic-orthostatic-hypotension-noh-in-subjects-w/. Accessed June 21, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-phase-2-study-of-the-efficacy-durability-and-safety-of-ampreloxetine-td-9855-a-norepinephrine-reuptake-inhibitor-given-once-daily-to-treat-neurogenic-orthostatic-hypotension-noh-in-subjects-w/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25676 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Effect of marijuana on Essential Tremor: A case report
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley